No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

HBM Healthcare Investments AG specializes in both direct investments and a fund-of-funds strategy, focusing exclusively on the healthcare sector, encompassing human medicine, pharmaceuticals, biotechnology, diagnostics, and medical technology. Its direct investments target a diverse range of companies, from early-stage startups and various venture and growth phases to mature private enterprises, unlisted emerging firms, and small-cap public entities. The firm also provides capital for company buyouts, growth initiatives, Private Investments in Public Equity (PIPEs), and the spin-off of product lines or departments from larger corporations, as well as the expansion or restructuring of established businesses. Through its fund-of-funds approach, HBM allocates capital to venture capital funds. Initial direct investments are typically made in companies whose primary products are either in clinical development or just prior to that stage. With a global investment mandate, the company emphasizes opportunities in North America, Europe, and the Asia Pacific region. For publicly traded companies, HBM generally prioritizes those that originated within its private investment portfolio. The firm often increases its commitment to portfolio companies through subsequent financing rounds or after their initial public offering. HBM frequently secures a seat on the portfolio company's Board of Directors and may acquire majority stakes. While primarily investing through equity, it also employs various other financial instruments, including convertible bonds, debt securities, structured products, and derivatives. Exits from these investments are typically facilitated through trade sales or initial public offerings.

• Fairfax India Holdings Corporation
• Pantheon International PLC
• Gimv N.V.
• Bure Equity AB (publ)
• Tri-Continental Corporation PFD $2.50
• Ashmore Group PLC
• BH Macro Limited
• MFF Capital Investments Limited